- Home
- CEE vs OVID Comparison
CEE vs OVID Comparison
Compare CEE & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- OVID
- Stock Information
- Founded
- CEE 1990
- OVID 2014
- Country
- CEE Germany
- OVID United States
- Employees
- CEE N/A
- OVID N/A
- Industry
- CEE Finance Companies
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- OVID Health Care
- Exchange
- CEE Nasdaq
- OVID Nasdaq
- Market Cap
- CEE 105.5M
- OVID 117.3M
- IPO Year
- CEE N/A
- OVID 2017
- Fundamental
- Price
- CEE $15.86
- OVID $1.45
- Analyst Decision
- CEE
- OVID Strong Buy
- Analyst Count
- CEE 0
- OVID 4
- Target Price
- CEE N/A
- OVID $3.13
- AVG Volume (30 Days)
- CEE 22.0K
- OVID 5.1M
- Earning Date
- CEE 01-01-0001
- OVID 11-13-2025
- Dividend Yield
- CEE 3.86%
- OVID N/A
- EPS Growth
- CEE N/A
- OVID N/A
- EPS
- CEE N/A
- OVID N/A
- Revenue
- CEE N/A
- OVID $6,651,000.00
- Revenue This Year
- CEE N/A
- OVID $1,086.57
- Revenue Next Year
- CEE N/A
- OVID N/A
- P/E Ratio
- CEE N/A
- OVID N/A
- Revenue Growth
- CEE N/A
- OVID 1070.95
- 52 Week Low
- CEE $7.80
- OVID $0.24
- 52 Week High
- CEE $10.32
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- CEE 54.09
- OVID 49.46
- Support Level
- CEE $15.41
- OVID $1.48
- Resistance Level
- CEE $16.07
- OVID $1.73
- Average True Range (ATR)
- CEE 0.43
- OVID 0.13
- MACD
- CEE 0.07
- OVID -0.03
- Stochastic Oscillator
- CEE 80.15
- OVID 13.16
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.